开发多价值的CAR-T细胞作为双重免疫疗法和调节剂
Quenton Rashawn Bubb1,2,3, Mohammad Balood2, Gabe Eduardo Seir2,4
1Stem Cell Biology and Regenerative Medicine Graduate Program, Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA 94305, USA.
研究人员开发了一种新的CAR T细胞疗法,针对儿科急性髓性白血病 (AML) 细胞的多个受体. 这种电动汽车T细胞疗法显示出更安全,非遗传毒性调节方案的前景,以防止干细胞移植后AML复发.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 造血干细胞移植 造血干细胞移植
背景情况:
- 血造干细胞移植 (HSCT) 后的儿科急性髓性白血病 (AML) 复发仍然是一个重大挑战,死亡率高.
- 目前的HSCT协议需要改进,以提高白血病细胞的消除和减少移植相关的毒性.
- 新的治疗策略对于克服AML复发的悲惨预后至关重要.
研究的目的:
- 研究血液生成细胞因子受体 (HCR) 作为儿科AML的潜在治疗点.
- 开发一种新型的嵌合抗原受体 (CAR) T细胞疗法,同时向多个AML相关的HCRs.
- 建立一个非遗传毒性调节方案的概念验证,以提高HSCT的有效性和安全性.
主要方法:
- 研究了小儿AML样本中KIT,MPL和FLT3血液生成细胞因子受体的表达.
- 设计了一种类别中的第一个与细胞外链接的协三价细胞因子 (ELECTRIC) CAR T细胞向KIT,MPL和FLT3.
- 评估了ELECTRIC CAR T细胞细胞毒性在体外和抗白血病活性在小鼠异种移植模型.
主要成果:
- 发现KIT,MPL和FLT3在儿科AML样本中高度共同表达.
- 电动汽车T细胞在体外表现出强烈的细胞毒性,对正常和恶性造血细胞.
- 在临床前的异种移植模型中,电动汽车T细胞疗法表现出抗白血病活性.
结论:
- 电动汽车系统代表了一种新的方法,可以同时针对儿科AML细胞上的多个HCR.
- 这种三价CAR T细胞疗法有可能成为更安全,非遗传毒性调节方案的基础.
- 开发的策略可能会导致儿童AML的HSCT更持久的疗效和降低毒性.
更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Tumor Immunotherapy
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
